



## Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

August 13, 2024 at 7:00 AM EDT

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis, clobetasol propionate ophthalmic suspension, 0.05% for postsurgical inflammation and pain, and developing the Optejet® device for use both in connection with its own drug-device therapeutic product for pediatric progressive myopia and dry eye as well as out-licensing for additional indications, today announced that the company will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, which is being held on Thursday, August 15<sup>th</sup>.

Management's pre-recorded company presentation can be accessed on-demand beginning at 7:00 am EDT on the day of the conference.

For additional information, or to register for the conference, please click [here](#). To arrange a virtual 1x1 meeting with Eyenovia management, please contact your H.C. Wainwright representative.

**PLEASE GO TO [MYDCOMBI.COM](https://www.mydcombi.com) FOR IMPORTANT SAFETY INFORMATION for MYDCOMBI™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%**

**PLEASE GO TO [CLOBETASOL.BID.COM](https://www.clobetasolbid.com) FOR IMPORTANT SAFETY INFORMATION for Clobetasol Propionate Ophthalmic Suspension 0.05%**

### About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery, which was approved by the FDA on March 4, 2024.

Eyenovia is also advancing late-stage development of MicroPine for pediatric progressive myopia (partnered with Arctic Vision in China and South Korea).

For more information, visit [Eyenovia.com](https://www.eyenovia.com).

The Eyenovia Corporate Information slide deck may be found at [ir.eyenovia.com/events-and-presentations](https://ir.eyenovia.com/events-and-presentations).

### Eyenovia Contact:

Eyenovia, Inc.  
John Gandolfo  
Chief Financial Officer  
[jgandolfo@eyenovia.com](mailto:jgandolfo@eyenovia.com)

### Eyenovia Investor Contact:

Eric Ribner  
LifeSci Advisors, LLC  
[eric@lifesciadvisors.com](mailto:eric@lifesciadvisors.com)  
(646) 751-4363

### Eyenovia Media Contact:

Eyenovia, Inc.  
Norbert Lowe  
Vice President, Commercial Operations  
[nlowe@eyenovia.com](mailto:nlowe@eyenovia.com)



Source: Eyenovia, Inc.